Advertisement

Reply to “Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients”

      We read with interest the article by Wang et al.
      • Wang SY
      • Giugliano RP.
      Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients.
      It reads “It affects 1 in 4 adults >40 years.” This statement may be misunderstood easily. Does it mean prevalence or incidence or lifetime risk? Is not clear. The lifetime risk of atrial fibrillation >40 years is 25%, not the prevalence or incidence.
      • Lip GYH
      • Banerjee A
      • Boriani G
      • Chiang CDE
      • Fargo R
      • Freedman B
      • Lane DA
      • Ruff CT
      • Turakhia M
      • Werring D
      • Patel S
      • Moores L
      Antithrombotic therapy for atrial fibrillation: CHEST guidelines and expert panel report.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang SY
        • Giugliano RP.
        Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients.
        Am J Cardiol. 2020; 00: 1-8
        • Lip GYH
        • Banerjee A
        • Boriani G
        • Chiang CDE
        • Fargo R
        • Freedman B
        • Lane DA
        • Ruff CT
        • Turakhia M
        • Werring D
        • Patel S
        • Moores L
        Antithrombotic therapy for atrial fibrillation: CHEST guidelines and expert panel report.
        Chest. 2018; 154: 1121-1201